FindTrial
Sign In

Preliminary study on the differential expression of non-coding genes in the treatment of advanced vitiligo with glucocorticoid

Identification of critical non-coding genes in the treatment of advanced vitiligo with glucocorticoid

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000040241
Enrollment
Unknown
Registered
2020-11-25
Start date
2020-11-30
Completion date
Unknown
Last updated
2021-02-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

vitiligo

Interventions

Health group versus cases group:Low-dose hormone therapy for 2-3 months for cases group

Sponsors

The Affiliated Changzhou 2nd People's Hospital of Nanjing Medical University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: According to the inclusion and exclusion criteria, the patients included in the case group were all treated for the first time, and they were not treated with corticosteroids, immunosuppressants, photosensitizers, and ultraviolet rays. Peripheral blood of vitiligo patients with advanced stage VIDA score> 3 points, systemic application of hormone therapy and low-dose hormone therapy for 2-3 months, were used to screen differentially expressed non-coding RNA using high-throughput gene chip technology.

Exclusion criteria

Exclusion criteria: Patients treated with glucocorticoids, immunosuppressants, photosensitizers and ultraviolet rays

Design outcomes

Primary

MeasureTime frame
Expression of non-coding RNA in serum;—

Countries

China

Contacts

Public ContactYan Cao

The Affiliated Changzhou 2nd People's Hospital of Nanjing Medical University

czeycy2018@163.com+86 15961426236

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026